Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts ; volume:16 ; number:1 ; day:22 ; month:7 ; year:2024 ; pages:1-13 ; date:12.2024
Alzheimer's research & therapy ; 16, Heft 1 (22.7.2024), 1-13, 12.2024

Creator
Wang, Yi-Ting
Therriault, Joseph
Tissot, Cécile
Servaes, Stijn
Rahmouni, Nesrine
Macedo, Arthur Cassa
Fernandez-Arias, Jaime
Mathotaarachchi, Sulantha S.
Stevenson, Jenna
Lussier, Firoza Z.
Benedet, Andréa L.
Pascoal, Tharick A.
Ashton, Nicholas J.
Zetterberg, Henrik
Blennow, Kaj
Gauthier, Serge
Rosa-Neto, Pedro
Contributor
SpringerLink (Online service)

DOI
10.1186/s13195-024-01509-5
URN
urn:nbn:de:101:1-2410072059371.866208151535
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Wang, Yi-Ting
  • Therriault, Joseph
  • Tissot, Cécile
  • Servaes, Stijn
  • Rahmouni, Nesrine
  • Macedo, Arthur Cassa
  • Fernandez-Arias, Jaime
  • Mathotaarachchi, Sulantha S.
  • Stevenson, Jenna
  • Lussier, Firoza Z.
  • Benedet, Andréa L.
  • Pascoal, Tharick A.
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gauthier, Serge
  • Rosa-Neto, Pedro
  • SpringerLink (Online service)

Other Objects (12)

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels

Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Related objects